Scientists have identified a rare inherited mutation in the CDK12 gene that is linked to an aggressive form of prostate cancer, according to research published this week. All five carriers identified in the study developed metastatic disease between the ages of 44 and 62, suggesting the mutation substantially raises the risk of early and aggressive cancer progression. The discovery adds to a growing body of evidence that inherited genetic factors play a significant role in prostate cancer outcomes and may explain why some men experience rapid disease spread despite otherwise favorable prognoses.
The finding could prompt expanded genetic testing for families with a history of prostate cancer, allowing carriers to be identified before symptoms emerge and potentially enabling detection while the disease remains treatable. Researchers caution that the study cohort was small and that further work is needed to confirm the mutation's prevalence and clinical implications across broader populations. Clinicians say the results nonetheless highlight the value of genetic counseling for affected families, while patient advocates have called for wider access to testing. Further studies are expected to examine whether targeted screening for CDK12 carriers improves survival outcomes.
Independent reporting synthesized from primary wires and global correspondents.